A pharmacokinetic and platelet function study of the combined administration of metoprolol and sulfinpyrazone to healthy volunteers.
In a double-blind study on healthy subjects who underwent three 3-week periods of treatment with metoprolol (M) + sulfinpyrazone (S), M + placebo, and S + placebo, pharmacokinetics and plasma levels of M were not affected by concurrent administration of S. Analysis of variance change-over demonstrated a significant difference between treatments only for serum uric acid levels. Analysis of post-treatment and baseline data within each treatment showed: decreased platelet count by M, lowered serum 6-keto PGF1 alpha by all three treatments, decreased serum TXB2 generation and arachidonic acid-induced platelet aggregation by S + M. No negative interaction between S + M was found.
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000097:blood / Q000494:pharmacology*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D010979:Platelet Function Tests; D013442:Sulfinpyrazone / Q000378:metabolism / Q000494:pharmacology*; D014527:Uric Acid / Q000097:blood
D014527:Uric Acid; D008790:Metoprolol; D013442:Sulfinpyrazone